Candid Therapeutics, Inc. (“Candid”), a clinical-stage biotechnology company redefining the treatment of autoimmune and inflammatory diseases through novel T-cell engagers (TCEs), today announced that it has been named to the prestigious 2025 Endpoints 11 list. The Endpoints 11 annually recognizes the most promising private biotech companies in the world driving innovation and shaping the future of the industry.
“We are thrilled to receive this recognition after just one year of officially launching the company,” said Dr. Ken Song, Chairman, President, and Chief Executive Officer of Candid. “We believe T-cell engagers represent a transformative modality for patients with debilitating inflammatory conditions, and this recognition underscores the progress our team has made advancing potentially first-in-class and best-in-class programs into the clinic.”
Candid is advancing a comprehensive pipeline of T-cell engagers, anchored by cizutamig, a first-in-class and potentially best-in-class BCMA-targeting TCE currently in clinical evaluation across multiple autoimmune indications. In addition, the company is progressing next-generation CD19- and CD20-targeting programs, including CND261 and CND319, alongside a robust discovery engine designed to expand TCE applications across a broad range of autoimmune and inflammatory diseases.
About Candid Therapeutics
Candid Therapeutics is a clinical-stage biotechnology company focused on transforming the treatment of autoimmune and inflammatory diseases through novel T-cell engager (TCE) platforms. Candid is advancing two lead B-cell depleting TCE antibody drug candidates, with a goal to broadly explore the potential of TCEs across multiple autoimmune diseases by targeting different B-cell protein targets, as well as evaluating different depths of B-cell depletion. Established in 2024 and headquartered in San Diego, CA, Candid is led by a team of entrepreneurial executives who have a track record of advancing programs into and through development and is supported by a distinguished syndicate of premier life science investors.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250919018956/en/
Contacts
Arvind Kush
info@candidrx.com
